Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Roth Capital Reiterates Buy on Sarepta Therapeutics (SRPT) as Advisory Meeting Set for January 22nd
October 15, 2015 9:52 AM EDTRoth Capital reiterated a Buy rating and $50.00 price target on Sarepta Therapeutic (NASDAQ: SRPT) as the advisory meeting has been set for January 22nd.
Analyst Debjit Chattopadhyay commented, "The PDUFA remains February 26th, 2016, but the delayed committee meeting has handed the bears a new... More
AdCom Changes Gives Sarepta Therapeutic (SRPT) Prep Time; Recommends Owning Into Briefing Doc Release
October 15, 2015 8:00 AM EDTOppenheimer analyst Christopher Marai reiterated an Outperform rating and $45 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying the January 22 Eteplirsen review gives the company more prep time. The analyst recommends owning the stock into drisapersen's briefing document release.
Marai commented, "Oct. 14, 2015, the FDA... More
Sarepta Therapeutics (SRPT) Announces Tentative Scheduling of FDA Review for Eteplirsen in DMD
October 14, 2015 12:44 PM EDTSarepta Therapeutics (NASDAQ: SRPT) announced the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is tentatively scheduled to review Sareptas New Drug Application (NDA) for eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD) amenable to... More
